申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
公开号:US11209421B2
公开(公告)日:2021-12-28
The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.
本发明提供了一种选择肿瘤患者接受抗肿瘤化合物治疗的体外方法,其中该方法包括测量所述患者的癌症样本中CDA(胞苷脱氨酶)的表达水平的步骤。当癌症样本的CDA表达水平低于参考表达水平时,表明患者适合使用选自表4化合物组成的组的抗肿瘤化合物,特别是氨基黄酮进行治疗。或者,当癌症样本的CDA表达水平高于参考表达水平时,表明患者适合使用选自表3化合物组成的组的抗肿瘤化合物,特别是达沙替尼进行治疗。